Cancer therapy via a combination of epigenetic modulation and immune modulation

a technology of epigenetic modulation and cancer therapy, applied in the direction of antibody medical ingredients, drug compositions, peptides, etc., can solve the problems of few effective chemotherapeutic options, and achieve dramatic tumor shrinkage, unexpected anti-neoplasia synergistic effects, and de novo expression.

Pending Publication Date: 2021-06-03
THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention relates to a method for treating or preventing neoplastic conditions in a person by administering an epigenetic modulating agent and an immune modulating agent. The treatment results in improved anti-neoplastic effects and enhances the efficacy of other therapies. The invention also includes the use of a MAC inhibitor, which blocks the formation of a pore that can cause harmful effects on cells. The therapy can stabilize or reduce cancer stem cells, cancer cells, tumors, and cancer-related symptoms. It can also improve the response rate, durability, and overall survival of cancer patients.

Problems solved by technology

(3, 4) Lung squamous cell carcinoma (LUSC) has no approved targeted therapies and few effective chemotherapeutic options beyond the first line of therapy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancer therapy via a combination of epigenetic modulation and immune modulation
  • Cancer therapy via a combination of epigenetic modulation and immune modulation
  • Cancer therapy via a combination of epigenetic modulation and immune modulation

Examples

Experimental program
Comparison scheme
Effect test

example 1

Observation of Anti-Tumor Efficacy of Combined Epigenetic and Anti-PD-1 Therapies

[0148]Five patients who received treatment on a clinical trial of epigenetic therapy (specifically, here. AZA treatments) for advanced treatment-refractory NSCLC were placed on trials for immunotherapy targeting the PD-1 / PDL1 immune tolerance checkpoint. Of these five patients, three experienced durable partial responses to immunotherapy now ongoing for 14 to 26 months, and the other two had stable disease that lasted 8.25 and 8.5 months, respectively. (see FIGS. 23 and 25) For comparison, 41-46% of NSCLC patients on these two trials of immunotherapy alone, one for anti-PD1 and the other for anti-PD-L1 therapy, passed 24 weeks without progression and 16-17% had durable partial response rates.(6-8)

example 2

mmatory Changes in Gene Expression Revealed to Increase with AZA Treatment

[0149]The clinical effect observed in Example 1 was believed to relate to the modes of action of both epigenetic treatments such as AZA and to anti-PD-1 immune tolerance checkpoint immunotherapies, such as anti-PD1 and / or anti-PDL1 antibodies (FIG. 1). The impact of AZA administration upon tumor-derived cell lines was then assessed for a number of genes, and revealed pro-inflammatory changes in expression of a wide number of genes to increase with AZA treatment. Specifically, as shown in FIG. 2, such effects were observed across genes CSAR; GM-CSF; MHCs; TNF-alpha; IL1 alpha / beta; IL6; IL8; IL-15; IL-15R; IL15RA; MMPs-TIMP1; COX2; OncostatinM; ICAM1; VCAM1; and TGF-betas and their receptors in epithelial cell lines, while effects were also observed for genes IFN-gammaR; TNF-alpha; MHCs; HLA B, C, G; TLR4; DAP12; CD13-macrophage maturation; IL-1RI; IL1 alpha / beta; MMPs-TTMP1; OncostatinM; and TGF-betas and thei...

example 3

g of STAT1, IFI27, OAS1, IFI16, HLA-A, IL18, and IL11 in Lung Cancer Cell Lines During Treatment Revealed Varying Levels of Molecular Response

[0150]Lung cancer-derived cell lines (including human NSCLC cell lines H838, H1299, H358, H1270 and H460; human adenocarcinoma / lung cell lines A549 and HCC827, and hepatocellular carcinoma / lung cell line HCC4006) were assayed for levels of STAT1 (FIG. 3), IFI27 (FIG. 4), OAS1 (FIG. 5), IFI16 (FIG. 6), HLA-A (FIG. 7), IL18 (FIG. 8), and IL11 (FIG. 9) during a treatment regimen including AZA administration over the course of 10 days. As shown in each of FIGS. 3-8, levels of these genes were also assessed in each of eight clinical subjects as shown (including two “good responders”, two “moderate responders” and four “non-responders”).

[0151]The above observations suggested that an adaptive resistance model of tumor-T cell interaction could be relevant to the PD-L1 upregulation-related response effects that were observed (FIG. 10). Indeed, while a ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Cancer therapies that combine epigenetic modulating agent(s) with immune modulating agent(s), which were remarkably identified to provide an improved treatment regimen over single agent therapy, are disclosed. In particular embodiments, the invention provides for improved treatment of NSCLC in patients via administration of exemplary immune modulating agents anti-PD-1 antibody or anti-PD-L1 antibody, which were observed to show enhanced activity in combination with the exemplary epigenetic modulating agent 5-deoxyazacytidine. Further, expression markers of responsive neoplastic cells are also disclosed.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application is related to U.S. Provisional Patent Application Ser. No. 61 / 874,185, filed Sep. 5, 2013. The entire contents of this patent application are hereby incorporated by reference herein.STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH[0002]This work was supported by the following grants from the Cancer Institute (NCI): Grant No CA058184. The government has certain rights in the invention.FIELD OF THE INVENTION[0003]The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of cancer and / or other proliferative diseases, disorders, or conditions. In certain embodiments, the invention specifically relates to combinations of therapies, including combination of epigenetic modulatory treatments with immunomodulatory therapies.BACKGROUND OF THE INVENTION[0004]Innovative strategies are needed to treat the world's most common cause of cancer death, non-small ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/706A61K38/15A61K39/395A61K31/167C07K16/28A61K45/06C12Q1/6886
CPCA61K31/706A61K38/15A61K39/395A61K31/167A61K2039/505C07K16/2818A61K39/3955A61K45/06C12Q1/6886C07K16/2827C12Q2600/106A61P35/00A61K2300/00C12Q2600/154
Inventor BAYLIN, STEPHEN B.PARDOLL, DREW M.TOPALIAN, SUZANNE L.
Owner THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap